Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc covers the period ending January 5, 2004. The report primarily details corporate governance matters, including applications for block listings of ordinary shares on the London Stock Exchange and disclosures regarding changes in directors' interests in company shares and American Depository Shares (ADSs).
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. The document focuses exclusively on share issuance and director holdings rather than financial performance.
Material Changes
- Share Issuance: The company applied for block listings totaling 396,825 Ordinary shares of 25p each to be admitted to the Official List. This includes 158,730 shares under the GlaxoSmithKline Share Option Plan - Ordinary and 238,095 shares under the GlaxoSmithKline Share Option Plan - ADS.
- Director Allocations: Non-executive directors received provisional allocations of Ordinary Shares and ADSs for the service period of October 1 to December 31, 2003, under both automatic and share election arrangements.
- Trust Transfers: The GlaxoSmithKline Employee Trust transferred 3,570 shares on December 23, 2003, and 16,442 shares on December 29, 2003, to participants in the SmithKline Beecham Employee Share Option Plan 1991.
- Retirement Plan Movement: The GlaxoSmithKline US Retirement Savings Plan saw a decrease in Ordinary Share ADRs from 18,727,604 to 18,647,046 as of December 31, 2003, at an average price of $46.62.
Guidance, Outlook, and Risks
The filing text does not provide a clear value for guidance, outlook, management commentary, risks, contingencies, or unusual items. The document serves as a regulatory notification of share movements and director interests.
Investor Verification Checklist
- Confirm the admission of the 396,825 new Ordinary shares to the London Stock Exchange Official List.
- Verify the final allocation of shares to non-executive directors following the provisional awards announced on January 5, 2004.
- Review the impact of the share transfers from the GSK Trust on the total outstanding share count.
- Monitor the valuation of the US Retirement Savings Plan holdings given the reported decrease in ADR count.